With an increasingly aged population, many patients will present with diffuse large B-cell lymphoma in their 70s and 80s. Recently, several randomized studies have confirmed the benefit of rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and showed a substantial improvement in the outcome of fit elderly patients. This article reviews the efficacy and toxicity of the current treatment regimens applied for the treatment of diffuse large B-cell lymphoma in elderly patients and provides practical recommendations for the management of these patients.

, , , , , , , , , , , , ,
doi.org/10.1007/s11912-008-0063-2, hdl.handle.net/1765/14300
Current Oncology Reports (Print)
Erasmus MC: University Medical Center Rotterdam

Lugtenburg, P., & Sonneveld, P. (2008). Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.. Current Oncology Reports (Print) (Vol. 10, pp. 412–419). doi:10.1007/s11912-008-0063-2